Quick Answer
Sigyn Therapeutics, Inc. reported Research And Development Expense of $773.3 thousand for the year ending 2024.
- Sigyn Therapeutics, Inc. showed a decrease of -3.1% in Research And Development Expense from 2023 to 2024.
- This data is from Sigyn Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2020 to 2024 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $2.0 thousand | Q1 2021: $116.5 thousand | Q2 2021: $139.7 thousand | Q3 2021: $227.5 thousand | Q1 2022: $228.3 thousand | Q2 2022: $154.7 thousand | Q3 2022: $133.8 thousand | Q1 2023: $147.8 thousand | Q2 2023: $219.2 thousand | Q3 2023: $215.2 thousand | Q1 2024: $232.6 thousand | Q2 2024: $240.4 thousand | Q3 2024: $206.2 thousand | Q1 2025: $8.8 thousand | Q2 2025: $7.5 thousand | Q3 2025: $29.7 thousand.
- Over the full 5 years of available data (2020 to 2024), Sigyn Therapeutics, Inc.'s Research And Development Expense has grown by 84.4%.
- Historical annual values: Fiscal year 2024: $773.3 thousand | Fiscal year 2023: $798.2 thousand | Fiscal year 2022: $657.7 thousand | Fiscal year 2021: $734.0 thousand | Fiscal year 2020: $419.4 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: